Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week

 Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week

Shots:

  • The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in ~3,923 adult patients on dialysis with anemia due to CKD
  • The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results across 1EPs & 2EPs
  • Vadadustat is an oral HIF-PH inhibitor designed to mimic the physiologic effect of altitude on oxygen availability and is also being evaluated in P-III PRO2TECT for anemia due to CKD in adult patients, not on dialysis. The company plans to submit NDA to the US FDA for anemia due to CKD in adult dialysis-dependent and non-dialysis dependent patients in 2021

Click here ­to­ read full press release/ article | Ref: Akebia | Image: Akebia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post